Villejuif

• A PHASE 1/2 STUDY OF ONCOBAX®-AK ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPY TO PATIENTS WITH ADVANCED SOLID TUMORS Ended
  2024-516711-24-00 7 2022-10-18 Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC)
• Phase 1/2 Study of ZN-c3 and Niraparib and ZN-c3 Monotherapy in Platinum-Resistant Ovarian Cancer Ended
  2024-515196-35-00 3 2022-09-29 Platinum-Resistant Ovarian Cance
• A Phase 3 Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease (Complication … Ended
  2024-516064-28-00 5 2022-09-27 Acute Graft Versus Host Disease
• A study of Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme Ended
  2024-517660-27-00 4 2022-09-22 Glioblastoma multiforme (GBM)
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 5 2022-09-13 Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
• A Study of SGN-B7H4V in Advanced Solid Tumors Ended
  2023-503389-22-00 1 2022-08-31 Fallopian tube cancer
• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S … Ended
  2024-513559-34-00 5 2022-07-19 Small Cell Lung Cancer (SCLC)
• First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leuk … Ended
  2023-508357-58-00 7 2022-07-04 Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myel
• Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (CLAUDIO-01) Ended
  2023-504441-31-00 7 2022-06-29 gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junct
• A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended
  2023-505455-44-00 9 2022-06-29 Solid tumours
• Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Ended
  2022-502773-41-00 9 2022-06-16 Relapsed/Refractory Classical Hodgkin Lymphoma
• A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination … Ended
  2024-511352-41-00 3 2022-06-13 advanced solid tumors
• PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCL … Ended
  2024-511975-14-00 9 2022-05-26 recurrent/refractory Ewing sarcoma
• A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling Ended
  2023-508617-16-00 9 2022-05-22 Solid Tumors Dependent on KIT or PDGFRA Signaling
• This study is to evaluate the safety and pharmacokinetics of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B … Ended
  2023-504795-20-00 3 2022-05-20 Relapsed/Refractory Aggressive Mature B-cell Neoplasms
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended
  2024-511996-13-00 5 2022-05-11 Previously untreated, unresectable, or metastatic melanoma
• A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low … Ended
  2024-514758-65-00 7 2022-05-04 metastatic castration-resistant prostate cancer (mCRPC)
• Tamibarotene/Venetoclax/Azacitidine in Previously Untreated Patients Selected for RARA-positive AML (SELECT-AML-1) Ended
  2024-510939-21-00 4 2022-04-01 RARA-positive acute myeloid leukemia
• Brightline-1: A study to compare brigimadlin (BI 907828) with doxorubicin in people with a type of cancer called dedifferentiated liposarcom … Ended
  2024-511361-11-00 10 2022-03-25 Advanced dedifferentiated liposarcoma
• PICASSO. Prospective randomIzed clinical trial assessing the tolerance and clinical benefit of feCAl tranSplantation in patientS with melanO … Ended
  2024-516100-42-00 4 2022-03-18 Melanoma
• Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program) Ended
  2024-512826-26-00 4 2022-03-07 Newly diagnosed, non-metastatic early-stage triple-negative or HER2+ b
• Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumours Ended
  2024-511071-16-00 3 2022-02-10 Solid Tumours
• Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J … Ended
  2023-505457-40-00 5 2022-02-02 Previously Untreated Advanced Gastric or Gastroesophageal Junction Can
• A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer Ended
  2023-506922-35-00 1 2022-01-24 Locally Advanced or Metastatic Solid Tumors with EGFR and/or HER2 Aber

Showing 841–864 of 961 trials